Which has better earnings and valuation, ALVOW or ENGNW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alvotech $559.42M N/A N/A N/A N/A enGene N/A N/A N/A N/A N/A

Is ALVOW or ENGNW more profitable?

Company Net Margins Return on Equity Return on Assets Alvotech N/A N/A N/A enGene N/A N/A N/A

Does the media favor ALVOW or ENGNW?

In the previous week, enGene had 12 more articles in the media than Alvotech. MarketBeat recorded 14 mentions for enGene and 2 mentions for Alvotech. Alvotech's average media sentiment score of 0.93 beat enGene's score of 0.15 indicating that Alvotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alvotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, APLMW or ENGNW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M N/A N/A N/A N/A enGene N/A N/A N/A N/A N/A

Is APLMW or ENGNW more profitable?

Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A enGene N/A N/A N/A

Does the media favor APLMW or ENGNW?

In the previous week, enGene had 11 more articles in the media than Apollomics. MarketBeat recorded 14 mentions for enGene and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.29 beat enGene's score of 0.15 indicating that Apollomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral enGene 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, ARAV or ENGNW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A enGene N/A N/A N/A N/A N/A

Is ARAV or ENGNW more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A enGene N/A N/A N/A

Which has stronger valuation and earnings, BIAFW or ENGNW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio bioAffinity Technologies $5.85M N/A N/A N/A N/A enGene N/A N/A N/A N/A N/A

Is BIAFW or ENGNW more profitable?

Company Net Margins Return on Equity Return on Assets bioAffinity Technologies N/A N/A N/A enGene N/A N/A N/A

Does the media prefer BIAFW or ENGNW?

In the previous week, enGene had 11 more articles in the media than bioAffinity Technologies. MarketBeat recorded 14 mentions for enGene and 3 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 0.97 beat enGene's score of 0.15 indicating that bioAffinity Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bioAffinity Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, BIVIW or ENGNW?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A N/A N/A N/A enGene N/A N/A N/A N/A N/A

Is BIVIW or ENGNW more profitable?

Company Net Margins Return on Equity Return on Assets BioVie N/A N/A N/A enGene N/A N/A N/A

Does the media prefer BIVIW or ENGNW?

In the previous week, enGene had 12 more articles in the media than BioVie. MarketBeat recorded 14 mentions for enGene and 2 mentions for BioVie. BioVie's average media sentiment score of 1.87 beat enGene's score of 0.15 indicating that BioVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioVie 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive enGene 2 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

enGene (ENGNW) Competitors

$0.24 -0.24 (-48.96%)

As of 04:00 PM Eastern

Compare

ENGNW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy enGene stock or one of its competitors? enGene's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does enGene compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and enGene (NASDAQ:ENGNW) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

In the previous week, enGene had 12 more articles in the media than Alvotech. MarketBeat recorded 14 mentions for enGene and 2 mentions for Alvotech. Alvotech's average media sentiment score of 0.93 beat enGene's score of 0.15 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$559.42M	N/A	N/A	N/A	N/A
enGene	N/A	N/A	N/A	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	N/A	N/A	N/A
enGene	N/A	N/A	N/A

Summary

Alvotech beats enGene on 2 of the 3 factors compared between the two stocks.

How does enGene compare to Apollomics?

Apollomics (NASDAQ:APLMW) and enGene (NASDAQ:ENGNW) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, enGene had 11 more articles in the media than Apollomics. MarketBeat recorded 14 mentions for enGene and 3 mentions for Apollomics. Apollomics' average media sentiment score of 0.29 beat enGene's score of 0.15 indicating that Apollomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
enGene	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	N/A	N/A	N/A	N/A
enGene	N/A	N/A	N/A	N/A	N/A

Summary

Apollomics beats enGene on 2 of the 3 factors compared between the two stocks.

How does enGene compare to Aravive?

Aravive (NASDAQ:ARAV) and enGene (NASDAQ:ENGNW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
enGene	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
enGene	N/A	N/A	N/A	N/A	N/A

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, enGene had 14 more articles in the media than Aravive. MarketBeat recorded 14 mentions for enGene and 0 mentions for Aravive. enGene's average media sentiment score of 0.15 beat Aravive's score of 0.00 indicating that enGene is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
enGene	Neutral

Summary

Aravive and enGene tied by winning 2 of the 4 factors compared between the two stocks.

How does enGene compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and enGene (NASDAQ:ENGNW) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

In the previous week, enGene had 11 more articles in the media than bioAffinity Technologies. MarketBeat recorded 14 mentions for enGene and 3 mentions for bioAffinity Technologies. bioAffinity Technologies' average media sentiment score of 0.97 beat enGene's score of 0.15 indicating that bioAffinity Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	N/A	N/A	N/A
enGene	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$5.85M	N/A	N/A	N/A	N/A
enGene	N/A	N/A	N/A	N/A	N/A

Summary

bioAffinity Technologies beats enGene on 2 of the 3 factors compared between the two stocks.

How does enGene compare to BioVie?

BioVie (NASDAQ:BIVIW) and enGene (NASDAQ:ENGNW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

In the previous week, enGene had 12 more articles in the media than BioVie. MarketBeat recorded 14 mentions for enGene and 2 mentions for BioVie. BioVie's average media sentiment score of 1.87 beat enGene's score of 0.15 indicating that BioVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioVie	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
enGene	2 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	N/A	N/A
enGene	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	N/A	N/A	N/A
enGene	N/A	N/A	N/A	N/A	N/A

Summary

BioVie and enGene tied by winning 1 of the 2 factors compared between the two stocks.

Get enGene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENGNW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ENGNW vs. The Competition

Export

Metric	enGene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	N/A	$3.75B	$7.09B	$12.99B
Dividend Yield	N/A	3.70%	2.57%	10.61%
P/E Ratio	N/A	6.01	210.49	21.56
Price / Sales	N/A	1,286.98	598.82	90.87
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	N/A	18.08	13.24	6.24
Net Income	N/A	-$13.23M	$3.45B	$347.70M
7 Day Performance	-51.09%	2.29%	2.03%	1.92%
1 Month Performance	-23.13%	0.79%	1.07%	1.05%
1 Year Performance	-62.15%	53.96%	67.58%	19.53%

enGene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ENGNW enGene	N/A	$0.25 -48.8%	N/A	N/A	$0.00	N/A	N/A	31	Gap Down
ALVOW Alvotech	N/A	$0.15 flat	N/A	N/A	$0.00	$559.42M	N/A	4	Upcoming Earnings
APLMW Apollomics	N/A	$0.02 +10.1%	N/A	-29.3%	$0.00	$8.50M	N/A	59	Short Interest Increase
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
BIAFW bioAffinity Technologies	N/A	$0.09 -0.6%	N/A	-30.7%	$0.00	$5.61M	N/A	10	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ENGNW) was last updated on 8/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

enGene (ENGNW) Competitors